Vaishali Pharma Ltd. Share Price

Overview

Vaishali Pharma Ltd. share price is currently ₹6.72, down by - ₹0.25 (3.59%) from its previous closing price of ₹6.97. The share price has declined -22.39% over the past month and declined -35.02% over the past year. The stock's 52-week low and high are ₹4.65 and ₹10.98, respectively. Vaishali Pharma Ltd. has a market capitalisation of ₹ 110.00 Cr. The share price was last updated on 23 Oct 2026, 10:36 AM IST.

Vaishali Pharma Ltd.
Vaishali Pharma Ltd.
VAISHALI
 ₹0.00
- ₹0.25
3.59%
Trading
 ₹0.00(%)1D

Updated: 23 Oct 2026, 10:36:26 am IST

Market Data

Open Price

 ₹7.34

Prev. Close

 ₹6.97
 ₹6.48

Day Low

 ₹7.34

Day High

 ₹4.65

52 Week Low

 ₹10.98

52 Week High

TradingTrading
CategoryMicro Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

20.36

Sector PE

37.48

PB Ratio

1.35

Sector PB

4.18

EPS

0.33

Dividend Yield

0.00

Today's Volume

63.948 K

5 Day Avg. Volume

72.629 K

PEG Ratio

-0.22

Market Cap.

₹ 110.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
Bonus1:1
15-Oct-202415-Oct-2024
Stock Split2:10
15-Oct-202415-Oct-2024

Mutual Fund Ownership

Mutual Fund Ownership will be available shortly.

About Vaishali Pharma Ltd. 👋

Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is in the pharmaceutical business, mainly dealing in active pharmaceutical ingredients, pharmaceutical formulations, surgical products, and veterinary supplements, operating in domestic and export markets. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceutical, oncology, surgical, and veterinary. The Company has manufactured and exported approximately 250 formulations and specializes in manufacturing tailor-made formulations. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/ anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, antiviral, antifungal, skeletal muscle relaxant, and anthelmintic drugs, excipients, topical steroids, corticosteroids, and enzymes. It has a global presence in Asia & Pacific, Africa, the Commonwealth of Independent States, America, and the Middle East.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Manjushri Sharma SEBI RA

Manjushri Sharma SEBI RA

10 Sep • 10:20 PM · SEBI-Registered Analyst

What Is ATR and Why Should Traders Follow It?

Any stock for Example

VAISHALI
ATR (Average True Range) is a technical indicator developed by J. Welles Wilder that measures the average volatility of a stock, index, commodity, currency, or crypto asset. Unlike indicators that predict whether price will go up or down, ATR tells traders how much an instrument typically moves over a given period. For example, if a stock has an ATR of ₹20, it indicates that the stock has been experiencing an average daily movement of roughly ₹20. A higher ATR means higher volatility, while a lower ATR indicates relatively calmer price action. Traders should follow ATR because volatility is essential for setting realistic Stop Losses and Targets. A Stop Loss placed too close to the entry can get triggered by normal market fluctuations even when the trade direction is correct. ATR helps traders give the trade enough breathing room according to the instrument's actual volatility. ATR can also help with position sizing and risk management. When volatility increases, traders can reduce their position size to keep the rupee risk under control. When volatility decreases, position size can potentially be adjusted accordingly. Another important use is identifying unusually strong price movement. If a stock moves significantly more than its normal ATR, it may indicate increased momentum, news-driven volatility, or a potential breakout. However, ATR should not be used alone to decide BUY or SELL trades. It works best alongside price action, support and resistance, trend, volume, moving averages, and momentum indicators. In simple words: ATR tells you how much the market is moving, helping you decide where to place your Stop Loss, Targets, and position size more intelligently.

See More
Saurab Jain

Saurab Jain

17 May • 1:31 PM · SEBI-Registered Analyst

Hindustan Aeronautics Limited Strengthening India’s Defence Manufacturing Ambitions

VAISHALI
Hindustan Aeronautics Limited plays a critical role in India’s aerospace and defence ecosystem through aircraft manufacturing, defence electronics, helicopters, and maintenance services. The company continues to benefit from India’s increasing focus on indigenous defence production and long-term military modernization programs. Rising government emphasis on self-reliance in defence manufacturing has strengthened order visibility and strategic importance for HAL. Expansion in fighter aircraft production, helicopters, and export opportunities continues to support long-term growth prospects. With strong institutional importance and technological capabilities, HAL remains a key pillar of India’s defence manufacturing sector. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes ***** must verify information before investing and consider their financial position & risk profile. please read full disclosure disclaimer in given link

See More
Palak Jain

Palak Jain

12 Dec • 5:09 PM · SEBI-Registered Analyst

IDEA
share price: Vi hits new 52-week high; Vaishali Parekh sets target at Rs 13

Vodafone Idea Share Price Target: Vodafone Idea shares are in strong uptrend with the counter hitting back-to-back 52-week high levels. On Friday (December 12), Vodafone Idea shares extended their previous session's gains and climbed to a new 52-week high of Rs 11.59 (up 3 per cent) -- a level seen for the first time since September 23, 2024. In the past two trading days, debt-laden Vodafone Idea shares have jumped 7 per cent. From the recent lows of Rs 9.93, touched on December 1, Vodafone Idea shares have shown a smart rally, zooming more than 15 per cent. Vi shares have gained in seven out of 10 trading sessions in December so far. At 12:40 AM, Aditya Birla Group-owned Vodafone Idea shares were quoting at Rs 11.58 on NSE with 61 crore equities changing hands. On BSE, Vi shares traded firmly in green near the day's high, quoting at Rs 11.57 around the same time with spurt in volume by more than 1.11 times. At the time of publishing this report, a total of 678 lakh equities of the telecom company changed hands on BSE versus the two-week average traded quantity of 674.84 lakh.

See More
Adarsh Nimborkar (SEBI IA)

Adarsh Nimborkar (SEBI IA)

5 Oct • 9:45 PM · SEBI-Registered Analyst

Stock Report: Max Healthcare Institute Ltd

MAXHEALTH
Company Overview Max Healthcare is one of India’s leading private hospital chains, with presence across North India. The company focuses on tertiary and quaternary care, with strong performance in Delhi NCR and other metros. Financial Performance • Q4 FY25 revenue: ₹1,909.74 crore (+32% YoY). • Q4 net profit: ₹319 crore (+27% YoY). • Occupied Bed Days rose 30% YoY; bed occupancy ~75%. • ARPOB stood at ~₹77,100. • FY25 revenue: ₹7,028.46 crore (+30% YoY). • FY25 net profit: ₹1,075.88 crore vs ₹1,057.64 crore in FY24. • FY25 operating EBITDA margin: 26.3% (down from 27.6% in FY24). Strategic Developments • Declared dividend of ₹1.50 per share for FY25. • Expanding capacity with three brownfield towers in Saket, Nanavati, and Mohali, adding ~1,500 beds in FY26. • Acquired land adjoining Vaishali hospital to expand operations. Strengths • Strong growth in revenue and profitability driven by higher occupancy and ARPOB. • Expansion pipeline to boost capacity and scale. • Well-positioned in high-demand regions like Delhi NCR. Risks & Challenges • Margins showing mild compression, cost pressures remain. • Execution risk in new capacity expansion. • High dependency on occupancy rates to sustain profitability. • Regulatory and pricing controls may impact earnings. My View Max Healthcare is growing steadily with robust revenue growth, improved occupancy, and strong ARPOB. Expansion plans are set to drive future growth, though margin pressure and regulatory challenges require close monitoring. The stock is attractive for long-term healthcare sector exposure.

See More
Palak Jain

Palak Jain

26 Sep • 8:55 PM · SEBI-Registered Analyst

MCX
share price target 2025: Vaishali Parekh's top stock to buy recommendation

MCX Share Price Target 2025: Veteran market expert and Vice President of Technical Research at Prabhudas Lilladher, Vaishali Parekh , has recommended buying MCX shares (Multi Commodity Exchange Of India Ltd). Speaking to ET NOW Swadesh on Friday morning (September 26), Vaishali Parekh said that MCX shares are showing strength. Vaishali Parekh said that the chart structure of of MCX is strong that the counter has potential to yield a return of up to Rs 500 or 6 per cent from hereon. "MCX could be a positional trade. My recommendation is to buy MCX shares. My positional target on MCX is Rs 8300. If MCX holds above Rs 8300, then the second target would be Rs 8500. Stop loss should be at Rs 7850," the market expert said.

See More
Ujvin Nevatia

Ujvin Nevatia

20 Dec • 4:40 PM · SEBI-Registered Analyst

Adani Group Commits to Transformative Investments in Bihar at Business Connect 2024

The Adani Group has announced transformative investments worth ₹20,000 crore to establish an ultra-supercritical thermal power plant in Bihar, showcasing its commitment to the state’s development under Chief Minister Nitish Kumar’s vision. This announcement was made by Pranav Adani, Director of

ADANIENT
a at the Bihar Business Connect 2024 summit, reflecting confidence in Bihar’s potential as an emerging economic hub. The thermal power plant alone will generate 12,000 jobs during pre-commissioning and 1,500 skilled jobs post-commissioning. Additionally, the Adani Group has earmarked ₹2,300 crore for expanding logistics, gas distribution, and agri-logistics, creating 27,000 jobs. Another ₹2,100 crore will fund the installation of 28 lakh smart meters in cities like Siwan, Gopalganj, and Vaishali, creating 4,000 local jobs. The group is also investing ₹2,500 crore to expand cement plant capacity to 10 million tonnes per annum and ₹1,000 crore for infrastructure projects such as Gati Shakti Railway terminals, inland container depots, and industrial warehousing parks. Having already invested ₹850 crore, generating 25,000 employment opportunities in Bihar’s logistics and agri-logistics sectors, the Adani Group’s new ventures are set to modernize infrastructure, boost employment, and accelerate economic growth. These projects highlight the group's commitment to sustainable development across energy, infrastructure, and technology. The Bihar Business Connect 2024, with participation from over 80 countries, underscores the state’s evolving business ecosystem and global appeal, paving the way for transformative partnerships and a brighter future for Bihar. Source: NDTV Profit No Recommendations

See More

Frequently Asked Questions

What is the share price of Vaishali Pharma Ltd.?

What is the market cap of Vaishali Pharma Ltd.?

Should I buy Vaishali Pharma Ltd. stock now?

What is the 52 week high and low of Vaishali Pharma Ltd.?

Is the Vaishali Pharma Ltd. stock good to buy?

Is Vaishali Pharma Ltd. a good buy for the long term?

Is Vaishali Pharma Ltd. overvalued or undervalued?

What is the PE and PB ratio of Vaishali Pharma Ltd.?

Start Now